Pharmaceutical companies are actively pursuing anti-CD19 strategies; indeed, anti-CD20 therapies do not directly target early B-cell differentiation stages (i.e., ALL) or B-cell malignancies resistant to anti-CD20 approaches. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.